James D. Nordin

James D. Nordin

Auto-generated profile, based on publicly available information

James D. Nordin

HealthPartners Institute, Minneapolis, MN, United States

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2003 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
KNKristin L. Nichol
Kristin L. Nichol
JNJames Nordin
James Nordin
JMJohn Mullooly
John Mullooly
RLRichard Lask
Richard Lask
KFKelly Fillbrandt
Kelly Fillbrandt
MIMarika Iwane
Marika Iwane
Upper respiratory tract illnesses have been associated with an increased risk of ischemic heart disease and stroke. During two influenza seasons, we assessed the influence of vaccination against influenza on the risk of hospitalization for heart disease and stroke, hospitalization for pneumonia and influenza, and death from all causes.

4 October 2007 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
KNKristin L. Nichol
Kristin L. Nichol
JNJames D. Nordin
James D. Nordin
DNDavid B. Nelson
David B. Nelson
JMJohn P. Mullooly
John P. Mullooly
EHEelko Hak
Eelko Hak
Reliable estimates of the effectiveness of influenza vaccine among persons 65 years of age and older are important for informed vaccination policies and programs. Short-term studies may provide misleading pictures of long-term benefits, and residual confounding may have biased past results. This study examined the effectiveness of influenza vaccine in seniors over the long term while addressing potential bias and residual confounding in the results.

1 March 2017 in Pediatrics
Verified
Journal Article
Closed access
PDF file
NBNicholas A. Beck
Nicholas A. Beck
JLJ. Todd R. Lawrence
J. Todd R. Lawrence
JNJames D. Nordin
James D. Nordin
TDTerese A. DeFor
Terese A. DeFor
MTMarc Tompkins
Marc Tompkins
BACKGROUND: Anterior cruciate ligament (ACL) tears are thought to occur with increasing frequency in young patients. No study has shown increased incidence over time. We hypothesized the incidence of ACL tears in young patients has increased over the past 20 years. METHODS: This descriptive epidemiology study is a retrospective review of insurance billing data of all patients aged 6 to 18 years with Current Procedural Terminology, Fourth Revision codes for ACL tear and reconstruction or International Classification of Diseases, Ninth Revision, Clinical Modification codes from 1994 to 2013. Injuries were normalized to persons per year enrolled in the insurance database based on age and sex. Analysis was performed based on sex and age (6–14, 15–16, and 17–18 years). RESULTS: The rate of ACL tears per 100 000 person-years averaged 121 ± 19 (range 92–151). All trends increased significantly except for the male 6- to 14-year-old and 17- to 18-year-old age groups. Overall there was an annual increase of 2.3%. Females had significantly higher incidence except in the 17- to 18-year-olds. Females peaked at age 16 years and males at age 17 years, with rates of 392 ACL tears and 422 ACL tears per 100 000 person-years, respectively. CONCLUSIONS: The incidence of ACL tears in pediatric patients increased over the last 20 years. Females were at higher risk except in the 17- to 18-year -old group. Peak incidence is noted during high school years. These data help target the most at-risk patients for ACL prevention programs.

1 July 2010 in Pediatrics
Verified
Journal Article
Closed access
PDF file
NKNicola P. Klein
Nicola P. Klein
BFBruce Fireman
Bruce Fireman
WYW. Katherine Yih
W. Katherine Yih
ELEdwin Lewis
Edwin Lewis
MKMartin Kulldorff
Martin Kulldorff
FDFor The Vaccine Safety Datalink
For The Vaccine Safety Datalink
OBJECTIVE: In February 2008, we alerted the Advisory Committee on Immunization Practices to preliminary evidence of a twofold increased risk of febrile seizures after the combination measles-mumps-rubella-varicella (MMRV) vaccine when compared with separate measles-mumps-rubella (MMR) and varicella vaccines. Now with data on twice as many vaccine recipients, our goal was to reexamine seizure risk after MMRV vaccine.METHODS: Using 2000–2008 Vaccine Safety Datalink data, we assessed seizures and fever visits among children aged 12 to 23 months after MMRV and separate MMR + varicella vaccines. We compared seizure risk after MMRV vaccine to that after MMR + varicella vaccines by using Poisson regression as well as with supplementary regressions that incorporated chart-review results and self-controlled analyses.RESULTS: MMRV vaccine recipients (83 107) were compared with recipients of MMR + varicella vaccines (376 354). Seizure and fever significantly clustered 7 to 10 days after vaccination with all measles-containing vaccines but not after varicella vaccination alone. Seizure risk during days 7 to 10 was higher after MMRV than after MMR + varicella vaccination (relative risk: 1.98 [95% confidence interval: 1.43–2.73]). Supplementary analyses yielded similar results. The excess risk for febrile seizures 7 to 10 days after MMRV compared with separate MMR + varicella vaccination was 4.3 per 10 000 doses (95% confidence interval: 2.6–5.6).CONCLUSIONS: Among 12- to 23-month-olds who received their first dose of measles-containing vaccine, fever and seizure were elevated 7 to 10 days after vaccination. Vaccination with MMRV results in 1 additional febrile seizure for every 2300 doses given instead of separate MMR + varicella vaccines. Providers who recommend MMRV should communicate to parents that it increases the risk of fever and seizure over that already associated with measles-containing vaccines.


1 September 2014 in Vaccine
Verified
Journal Article
Closed access
MMMichael M. McNeil
Michael M. McNeil
JGJulianne Gee
Julianne Gee
EWEric S. Weintraub
Eric S. Weintraub
EBEdward A. Belongia
Edward A. Belongia
GLGrace M. Lee
Grace M. Lee
FDFrank DeStefano
Frank DeStefano